By Ekta Batra Dec 14, 2021 3:24:18 PM IST (Published)
The company's subsidiary Ichnos Sciences has entered into an agreement with Almirall to out-licence a drug under development called ISB 880. ISB 880 is a drug under study for autoimmune conditions and oncology.
Glenmark Pharmaceutical was buzzing in trade on Tuesday. The company's subsidiary Ichnos Sciences has entered into an agreement with Almirall to out-licence a drug under development called ISB 880.
ISB 880 is a drug under study for autoimmune conditions and oncology.
According to the agreement, Ichnos will receive upfront payment of 20 million euros from Almirall.
To know more about the deal, CNBC-TV18 spoke to Glenn Saldanha, CMD of Glenmark Pharmaceutical.
Watch video for more.